Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4719966 | 0.86 | TSHR (0.58) | TDP1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL572190 | 0.85 | TDP1 (0.58) | TDP1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL12798874 | 0.85 | TDP1 (0.62) | TDP1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL2929031 | 0.85 | TDP1 (0.62) | TDP1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL30989211 | 0.85 | TDP1 (0.62) | TDP1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL11079242 | 0.83 | TDP1 (0.60) | TDP1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL31423774 | 0.83 | TDP1 (0.60) | TDP1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL515466 | 0.82 | MAPT (0.54) | TDP1MAPTALDH1A1POLBCYP3A4 | |
| SCHEMBL7253733 | 0.81 | TDP1 (0.58) | TDP1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL16655546 | 0.81 | TDP1 (0.58) | TDP1MAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119121616-A | Washable crease-resistant fabric and preparation method thereof | 江苏翔鹏染整科技有限公司 | 2024-12-13 | — | — | CN | claimed |
| EP-0182330-B1 | USE OF 2-NITROANILINE DERIVATIVES AS HAIR DYEING AGENTS, AND 2-NITROANILINE DERIVATIVES | Wella Aktiengesellschaft (DE) | 1991-05-15 | — | — | EP | claimed |
| EP-0182330-A2 | Use of 2-nitroaniline derivatives as hair dyeing agents, and 2-nitroaniline derivatives | Wella Aktiengesellschaft (DE) | 1986-05-28 | — | — | EP | claimed |
| CN-119121616-A | Washable crease-resistant fabric and preparation method thereof | 江苏翔鹏染整科技有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-119121616-A | Washable crease-resistant fabric and preparation method thereof | 江苏翔鹏染整科技有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20170233375-A1 | CANCER THERAPEUTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-08-17 | — | — | US | disclosed |
| US-9156822-B2 | Functionally selective ligands of dopamine D2 receptors | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-13 | — | — | US | disclosed |
| EP-1606268-B1 | 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS | ABBVIE INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | disclosed |
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080166362-A1 | New effector conjugates, process for their production and their pharmaceutical use | BERGER MARKUS | 2008-07-10 | — | — | US | disclosed |
| US-4230868-A | α-Alkyl-α-hydroxybenzyl-substituted 1-sulfonylbenzimidazoles | ELI LILLY AND COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
| US-4216313-A | Antiviral thiazinyl benzimidazoles | ELI LILLY AND COMPANY (US) | 1980-08-05 | — | — | US | disclosed |
| US-4202698-A | DYE BLEACH CATALYSTS | CIBA-GEIGY AG (CH) | 1980-05-13 | — | — | US | disclosed |
| US-4196125-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4174454-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1979-11-13 | — | — | US | disclosed |
| US-4150028-A | Antiviral thiazolinyl benzimidazoles | ELI LILLY AND COMPANY (US) | 1979-04-17 | — | — | US | disclosed |
| US-4118742-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4118573-A | ANTIVIRAL AGENTS | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4018790-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233375-A1 | CANCER THERAPEUTICS | RUNX1, CBFB, MCL1 | TDP1 3506/4885MAPT 3939/4885ALDH1A1 1660/4885 |
| US-20080166362-A1 | New effector conjugates, process for their production and their pharmaceutical use | EPOR, TIE1, TEK | TDP1 4191/4885MAPT 3760/4885ALDH1A1 1845/4885 |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | DRD2, AVPR2, NTSR2 | TDP1 2206/4885MAPT 1375/4885ALDH1A1 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.